Hello. This is Daily Stock, delivering reliable investment information and rigorous analysis after the Korean market close.
![Image: /stdaily/uploads/202606/gen_6a2130d7db8039.72993484.png]
Summary
While the KOSDAQ market has recently experienced volatility due to short-term corrections in the bio sector and a lack of clear market leaders, major conference milestones and pipeline clinical momentum are coming back into focus starting in June.
In particular, the American Diabetes Association (ADA 2026) meeting on June 5, global big pharma entering new clinical trials, and domestic dual-antibody companies applying for investigational new drug (IND) amendments are drawing significant attention.
Accordingly, we closely examine the technological prowess and valuations of KOSDAQ's leading pharmaceutical and biotech players—Alteogen, ABL Bio, and Peptron—which possess platform competitiveness and clear clinical milestones.
Market Overview
On June 4, 2026, the KOSDAQ index closed at 1,049.73. The KOSPI closed at 8,639.41, the Nasdaq at 26,853.98, and the USD/KRW exchange rate stood at 1,529.90 won.
Amid recent market concentration and a strong dollar stance, our Fear and Greed Index shows the KOSPI Fear & Greed is currently Neutral (56.6), compared to Neutral (57.1) a week ago, Greed (65.7) a month ago, and Fear (37.4) three months ago.
Nasdaq's Fear & Greed is also currently Neutral (54), compared to Greed (60.1) a week ago, Greed (66.9) a month ago, and Neutral (54.9) three months ago, indicating that overall market sentiment has cooled down a notch.
Although the KOSDAQ index suffered a short-term correction—dropping nearly 200 points after peaking at 1,226.18 on April 27—selective rebounds are being observed, centered on individual stocks with valid pipeline momentum.
Financial Analysis
The stock prices and major financial performances of KOSDAQ's three bio platform companies as of June 4, 2026, are diverging based on the maturity of their respective pipelines.
| Stock Name (Ticker) | Closing Price (June 4, 2026) | Market Cap | Major Clinical & Contract Momentum |
|---|---|---|---|
| **Alteogen** (196170) | 350,000 KRW (▽1.96%) | Approx. 19.13T KRW | Beneficiary of Calderaship's FDA Breakthrough Therapy designation & accelerating Keytruda SC royalties |
| **ABL Bio** (298380) | 105,600 KRW (▽1.40%) | Approx. 6.00T KRW | Submitted IND amendment for ABL503 (Lagistomig) combination therapy Phase 1 on June 4 |
| **Peptron** (087010) | 268,000 KRW (▽0.92%) | Approx. 6.25T KRW | Scheduled to present clinical data for 1-month sustained-release Semaglutide (PT403) at ADA 2026 |
Alteogen demonstrated high profitability from platform technology exports, posting Q1 2026 consolidated revenue of 71.6 billion KRW and an operating profit of 39.3 billion KRW, translating to an operating margin of 54.9%.
For ABL Bio, license-out revenues account for 96.95% of total sales. The company has entered the "ABL 2.0" phase of self-sustainability, pursuing large-scale deals post-Phase 1.
Peptron is developing obesity and diabetes candidates based on its proprietary SmartDepot long-acting platform technology, focusing on establishing global partnerships ahead of top-line revenue growth.
![Image: /stdaily/uploads/202606/gen_6a2130e556f479.50870869.png]
Valuation
Unlike traditional manufacturing companies, drug-development platform companies are valued based on the future value of their pipeline and the scale of recurring royalty inflows.
In the case of Alteogen, as MSD's (Merck) Keytruda SC formulation "Keytruda Curex" launched in the US and Europe, royalty payments—estimated at around 2% of net sales—are expected to gradually begin starting in Q2.
Additionally, its target market expanded through the recent entry into a Phase 3 combination trial with Calderaship. Analyst reports suggest that annual royalty income alone could exceed 1 trillion KRW by 2029–2030, when Dupixent SC and Enhertu SC are commercialized.
ABL Bio is being revalued based on the potential of its blood-brain barrier (BBB)-penetrating platform, Grabody-B, and its immuno-oncology platform, Grabody-T, aiming for higher-value technology transfers as clinical data accumulates.
For Peptron, joint development with global big pharma like Eli Lilly and whether the SmartDepot evaluation converts into a definitive license agreement are the key variables. The abstract data of PT403 to be released at ADA 2026 is seen as a clue to overcome its current negative P/E ratio.
Expert & Institutional Analysis
Securities industry experts analyze that while the pharmaceutical and biotech sectors were excessively battered during KOSDAQ's sharp adjustment, a process of separating wheat from chaff will begin in earnest starting with the June conference season.
Daeshin Securities pointed out that Alteogen's patent-related risks in the US have been substantially mitigated by the US Patent Trial and Appeal Board's (PTAB) invalidation ruling, and that it is currently discussing additional licensing deals with over 10 global pharmaceutical firms under Material Transfer Agreements (MTAs).
While Daol Investment & Securities positively evaluated the value of ABL Bio's bispecific antibody and BBB shuttle technology, it has adopted a conservative approach by adjusting pipeline discount rates for individual companies to reflect overall market liquidity shifts.
Investment experts note that HLB's FDA approval decision for its liver cancer drug and Kolon TissueGene's announcement of TG-C US Phase 3 top-line results, both expected in July, will serve as critical turning points for capital inflow into the biotech sector in the second half of the year.
Risk Factors
First, macroeconomic instabilities—such as prolonged high interest rates and the USD/KRW exchange rate hovering in the mid-1,500s—increase financial burdens for small and mid-sized biotech companies that rely heavily on external funding.
Second, while IND submissions and amendments are normal procedures in drug development, unexpected requests for information (Clinical Holds) or delays in clinical schedules can trigger sharp volatility.
Third, due to the nature of platform deals, there is always the risk that option agreements or MTAs may fail to convert into final definitive agreements, or development may be halted if partners change their R&D priorities.
Investment Outlook
With KOSDAQ searching for a support level near 1,049, bio investments based on simple expectations are highly vulnerable to volatility.
A selective approach is required, focusing on proven platforms that can directly demonstrate clinical data or generate cash flow (royalties) by being applied to blockbuster drugs that are already commercialized.
Rather than short-term momentum plays tied to conference abstracts and clinical calendars, a strategy of monitoring technological scalability and the resolution of patent risks from a long-term perspective seems appropriate.
Investor Checklist Q&A
Q1. What is the most important event to watch in the bio sector in June?
A1. The American Diabetes Association (ADA 2026) meeting starting June 5. Clinical abstract data for PT403, a 1-month sustained-release obesity and diabetes treatment candidate developed by Peptron, will be released to the global market.
Q2. Is it true that Alteogen's Keytruda SC royalty benefits are accelerating?
A2. Yes. MSD's next-generation KRAS inhibitor, Calderaship, was designated as an FDA Breakthrough Therapy in late May. "Keytruda Curex," which incorporates Alteogen's technology, has been positioned as a combination partner in its subsequent Phase 3 trial, raising expectations for commercialization synergy and accelerated royalty growth.
Q3. What is the significance of the IND amendment application submitted by ABL Bio on June 4?
A3. It is a measure to expand the clinical development strategy of its immuno-oncology candidate ABL503 (Lagistomig) from monotherapy to a combination therapy with PD-1 inhibitors. This is interpreted as a strategy to maximize pipeline value across new cancer indications.
Q4. Have the patent risks for platform bio companies been resolved?
A4. In the case of Alteogen, concerns over patent disputes with competitors have been greatly eased due to the US PTAB's recent invalidation and dismissal decisions. However, for other companies, investors must individually verify the survival of prior patents related to linkers or payloads conjugated to their respective platforms.
Q5. What July schedule will dictate the flow of the KOSDAQ bio sector in the second half?
A5. Market attention is highly focused on the FDA's final decision on HLB's liver cancer drug approval and Kolon TissueGene's announcement of US Phase 3 top-line results for TG-C, its degenerative arthritis treatment.